Wound Care Biologics Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

Page: 215 | Report Code: LS24072901 | Research Suite: Report (PDF) & Market Data (Excel)

NOTE: Due to exhaustive nature of content, full ToC can't be uploaded. Please request Sample Pages to receive full table of content. 

The global wound care biologics market was valued at USD 1.7 billion in 2022, and a CAGR of 4.5% is expected during the forecast period. The increasing prevalence of chronic wounds and surgical wounds is driving significant growth in the market. The increasing number of cases of chronic wounds in the last decade is driving growth in the market.

Increasing cases of road accidents are driving the demand for wound care in the market significantly. The increasing prevalence of chronic diabetes is the key factor behind the significant growth in the market. Increasing incidences of diabetes are the main reason behind significant growth in the market.


Growth Drivers

Increasing geriatric population and increasing growth in accidental cases all over the world are driving the demand in the wound care biologics market. Healing ulcers in a timely manner is the demand of the time, and the increasing number of cases of chronic diabetes worsens the condition of the wound. The need to treat venous leg ulcers is driving the growth of the market significantly.

Increasing healthcare spending and increasing demand for advanced wound treatment options are driving growth in the market. The increasing prevalence of chronic diseases is the main cause of the growth in the market. Rising healthcare expenditure and increasing awareness of better health are driving significant growth in the market. Increasing awareness about wound care is driving growth in the market.

Segmentation

By Wound Types

·         Ulcers

·         Surgical and Traumatic Wounds

·         Burns

By End-User

·         Hospitals

·         Ambulatory Surgical Centers

·         Burn Care Centers and Wound Clinics

By Products

·         Biological Skin Substitutes

·         Topical Agents

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Wound Care Biologics Wound Type Segmentation

On the basis of the wound type, the wound care biologics are segmented into ulcers, surgical and traumatized wounds, and burns. Ulcers like chronic wounds, for example, diabetic foot ulcers, venous leg ulcers, and pressure ulcers, are prevalent worldwide. It affects a significant number of patients, creating a large demand for effective treatment options, including biologics. Many ulcers are chronic in nature, meaning they persist over an extended period of time and often require advanced treatment modalities such as biologics to facilitate healing.


Biologics have shown clinical effectiveness in healing, especially in cases where traditional treatments were ineffective. Ulcers, particularly diabetic foot ulcers and venous ulcers, are complicated to treat due to diabetes or venous insufficiency. The increasing prevalence of chronic diseases, such as diabetes and the aging population, contributes to a growing market demand for advanced wound care solutions, including biologics targeted at ulcer management.

Wound Care Biologics Market End-User Segmentation

On the basis of the end-user, the wound care biologics market is segmented into hospitals, ambulatory surgical centers, burn care centers, and wound clinics. Hospitals are the leading segment and are expected to dominate the market during the forecast period because they have specialized wound care centers equipped with advanced facilities and expertise to handle complex cases requiring biological treatments. It often attracts patients needing intensive care and treatment for chronic wounds.

Hospitals generally have better infrastructure, including surgical units, sterile environments, and intensive care units, which are crucial for administering biological treatments safely. Hospitals house a variety of medical specialists, including surgeons, wound care specialists, and nurses trained in biologic therapies. This expertise ensures proper diagnosis, treatment planning, and timely care. Ambulatory surgical centers are second to hospitals, and they ensure the treatment required for the serious patient inside the ambulance.

It is designed to provide outpatient surgical and medical procedures in a more convenient and accessible setting compared to hospitals. This appeals to patients who require biological treatment for wounds but don’t need overnight hospitalization. It requires generally low overhead costs compared to hospitals, which does translate to lower overall treatment costs for patients. Receiving wound care biologics. Its affordability makes it an attractive option. Over all, it provides a valuable alternative for patients. The increasing number of chronic diabetes patients is driving growth in the market.

Regional Outlook

On the basis of the regions, the wound care biologics market is segmented into 5 parts: Asia Pacific, North America, Latin America, the Middle East, and Europe. North America is the leading segment and is expected to dominate the market during the forecast period because the United States of America and Canada boast highly developed healthcare infrastructure with sophisticated medical facilities and advanced technologies. This facility has led to widespread adoption of advanced wound care products, including biologics. The region has one of the highest healthcare expenditures globally, which supports the adoption of expensive biologics for wound care.

This financial capability allows hospitals and healthcare providers to invest in cutting-edge treatments. With the growing geriatric population, there is an increased chance of chronic wounds, such as diabetic ulcers and pressure ulcers. North America has stringent regulatory standards, enforced by agencies like the FDA in the United States and Canada, which ensure the safety and efficacy of wound care biologics. The region is a hub for medical research and innovation, leading to continuous advancements in biological therapy for wound care. It includes development in areas such as tissue engineering, growth factors, and stem cell therapies.

High awareness among healthcare providers and patients is driving growth in the market significantly. This awareness leads to the early adoption of these products in clinical settings. Asia Pacific is the second-leading segment due to the rapidly increasing population and increasing number of patients with chronic diabetes. Rising disposable income and urbanization in countries like China and India have forced people to migrate to these countries.


The increasing number of diabetes patients is driving growth in the market significantly. Increasing cases of accidents in these regions are the main cause of the growth in the market. Europe, due to an increasing geriatric population and an increasing number of chronic diabetes patients, is driving growth in the market. England, Russia, Germany, France, Italy, and Sweden are witnessing growth in the wound care biologics market.

Key Players

·         Smith and Nephew Plc

·         Organogenesis Inc.

·         MIMEDX

·         Integra Lifesciences

·         Stryker Corporation

·         Wright Medical

·         Derma Sciences

·         Osiris Therapeutics

·         Kerecis

·         Organogenesis Inc.

·         Molnlycke Healthcare AB

·         Other Players

Buy Report